Christine Michel

New acc |
Breast cancer medical Oncologist, work at MSKCC

[Christine Michel @Oncologist_ch]

@Dr_Oncologista May Allah grant your dad a speedy and complete recovery🙏🏻🤍

[NEJM @NEJM]

Original Article: Talquetamab–Daratumumab in Relapsed or Refractory Myeloma (phase 3 MonumenTAL-3 trial) https://t.co/rVgRU4aERe

#Hematology

[Dr. Patrick Hwu @PatrickHwuMD]

🧬 #ScienceSaturday

❓ What if we could help T cells not only find solid tumors, but also keep fighting once they get there?

➡️ In a new study published in @Nature, researchers used #CRISPR to search across the genome for genes that may be holding human T cells back inside solid tumors.

➡️ Instead of doing the screen only in a lab dish, the team developed a way to study human T cells inside tumor-bearing mice, where they face many of the same barriers that can weaken T cells in real tumors.

➡️ They identified two important “brakes.” One, called P2RY8, appeared to make it harder for T cells to enter tumors. Another, called GNAS, helped transmit several of the suppressive signals tumors use to shut T cells down.

➡️ When researchers removed GNAS, the engineered T cells were better able to stay active, survive and kill cancer cells despite those suppressive signals. In one melanoma model, all 6 mice treated with GNAS-edited CAR T cells achieved durable tumor clearance.

➡️ The approach also improved tumor control across several other preclinical models, including pancreatic, lung, uterine sarcoma and gastroesophageal cancers, as well as different types of engineered T-cell therapies.

➡️ Even more interesting, removing both P2RY8 and GNAS appeared to tackle two problems at once: helping more T cells get into the tumor and helping them resist being switched off once they were there.

💡 The big idea: instead of engineering #TCells with just one added weapon, we may be able to make them better equipped to overcome the hostile environment of solid tumors. @UCSF @jccarnevale @MarsonLab @j_eyquem @ShifrutLab @UCSFCancer @GladstoneInst @parkerici @StanfordMed @TelAvivUni @igisci @NaturePortfolio

Read more: https://t.co/zTJpFtFHeB

[Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista]

DESTINY-Lung04: A Potential Paradigm Shift in 1L HER2-Mutant NSCLC 🫁

T-DXd significantly improved PFS vs platinum–pemetrexed + pembrolizumab
The first randomized Phase III evidence of a HER2-directed therapy outperforming contemporary 1L SOC

https://t.co/KJ3uBAjCfq

@OncoAlert

[Paolo Tarantino @PTarantinoMD]

Glad to see our article on the RW activity of post-T-DXd regimens among the most read on @JNCI_Now! It addressed a simple question: what works best among patients with MBC and prior T-DXd? (Unsurprising) answer: switching mechanism of action of the chemo. https://t.co/34Spb8Gs7M

[Annals of Oncology @Annals_Oncology]

���article in press: Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304) @Prof_IanD; @ChrisSweens1
https://t.co/3nLwBNnI4m

[Christine Michel @Oncologist_ch]

@Dr_Oncologista @Fixerguy Ameen 🙏🙏

[Annals of Oncology @Annals_Oncology]

🆕Article of the Month podcast🎧: @tompowles1 discusses "GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults" with author @AparnaKamatMD
https://t.co/TZTb5MyR9T
For the full article see:
https://t.co/BpguTUNswI

[Oncology Brothers @OncBrothers]

Here are the options we had a chance to touch on with @myelomaMD and #MaxMerz during our discussions on Early and Late Relapse/Refractory #MultipleMyeloma

#OncTwitter #HemeTwitter @OncUpdates @OncoAlert

[Hidehito HORINOUCHI @HHorinouchi]

🔥The next generation of antibody–drug conjugates
🆙 @NatureMedicine
🎯Pace of ADC innovation now exceeds clinical trial capacity — integrated strategy urgently needed
🎯Multi-chemistry ADC libraries with distinct constructs & DARs will enable tumor biology-aligned personalized treatment
🎯Molecular tools to predict ADC sensitivity & optimal use in early-stage cancers are key next steps
🎙 @FerMosele @YukinoriOzaki @jsoriamd @FAndreMD
@OncoAlert @Larvol
https://t.co/NPqTSjvFcN

[Mario Balsa @MarioBalsaMD]

🚨 The next generation of antibody–drug conjugates (Perspective: @FerMosele @jsoriamd @FAndreMD)
https://t.co/lRvwG68y5N

🎯 Multi-dimensional biomarkers may enable personalized ADC selection
⚡ Diversified constructs & optimized drug-to-antibody ratios could improve efficacy
👀 Faster development frameworks are needed to match the pace of ADC innovation

The next generation of ADCs should carry better ideas 🤔

@OncoAlert
@OncoReporte @myESMO @_SEOM

[Dana-Farber News @DanaFarberNews]

Researchers found biological evidence that vitamin D changes tumor microenvironment in stage I-3 colon cancer. Now in @JAMA_current, lead author @KimmieNgMD explains why those changes should be investigated, as they may be linked to anti-cancer activity. ➡️ https://t.co/PRkQGmyGmu

[Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista]

FeDeriCa final analysis confirms that fixed-dose subcutaneous pertuzumab/trastuzumab delivers comparable long-term outcomes to IV therapy, with durable 4 yrs efficacy, reassuring cardiac safety, and no new safety signals.

https://t.co/hcNPOVxz9Z

@OncoAlert #BreastCancer #bcsm

[Christine Michel @Oncologist_ch]

@Dr_Oncologista 🥰❤❤❤❤❤

[Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista]

Watching the #FIFAWorldCup Final 🏆 with @Oncologist_ch 😍✨⚽

[OncoAlert @OncoAlert]

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study

https://t.co/sdKlAHvj5L

The phase 2 HER2CLIMB-04 trial evaluated tucatinib plus trastuzumab deruxtecan (T-DXd) in patients with previously treated 🧬 HER2-positive advanced/metastatic #BreastCancer . Among 70 patients, the combination achieved a confirmed objective response rate of 51.4%, median duration of response of 11.9 months, and progression-free survival of 11.5 months. Diarrhea was the most common adverse event but was reduced with prophylactic antidiarrheal therapy, supporting tolerability of dual HER2 targeting.

@nlinmd
@DrLisaCarey
@ErikaHamilton9
@drjenspecht

@hoperugo
@JavierCortesMD
@FAndreMD
@matteolambe
@ErikaHamilton9
@DrSGraff
@aftimosp
@BianchiniGP
@ElisaAgostinett
@raalbany
@jamecancerdoc
@Icro_Meattini
@stolaney1
@maryam_lustberg
@LoiSher
@stage4kelly
@to_be_elizabeth
@RebeccaDSing
@double_whammied
@itsnot_pink
@coffeemommy
@FernandoOnco
@JaniceTNBCmets
@TanjaSpanic
@christeeny513
@stage4kelly
@Prof_Nadia_H
@MammaMiaMagazin
@E_de_Azambuja

[Dr Preetam Jain @PreetamJainOnco]

BREAKING NEWS !

Finally... a targeted therapy for HR+/HER2− metastatic breast cancer with PIK3CA wild-type disease.

🧬 Key clinical pearls:

✅ FDA-approved Gedatolisib

✅ After progression on CDK4/6 inhibitor + AI

✅ Triplet PFS: 9.3 vs 2.0 months (HR 0.24)

✅ New option for ~60% of HR+/HER2− MBC patients

Precision oncology continues to evolve.

#ASCO #BreastCancer #MedOnc #MedicalOncology #PrecisionOncology #Gedatolisib #PIK3CA #HRPositive #HER2Negative #MetastaticBreastCancer #TargetedTherapy #Oncology #CancerResearch #DrPreetamJain

@oncodaily @OncoDailyBreast

[Paolo Tarantino @PTarantinoMD]

Results from HER2CLIMB-04 show that combining T-DXd with tucatinib does not lead to higher efficacy than T-DXd monotherapy. Follows the disappointing results of HER2CLIMB-02 (T-DM1 + tuc). Tucatinib stabilizes HER2 on the membrane: bad partner for ADCs? https://t.co/L3o8mddLjL

[Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista]

@ASCO Reaffirms a Long-Standing Principle: Evidence Supports Smarter Surveillance, Not More Surveillance.
https://t.co/3qtkpKH5iC

@OncoAlert #BreastCancer #Bcsm @JCO_ASCO https://t.co/6sOabrCgxU

[NEJM @NEJM]

Multiple sclerosis, a common autoimmune disease of the central nervous system, affects the brain, optic nerves, and spinal cord. Its hallmark effects are inflammation, demyelination, and neurodegeneration. 🔗 https://t.co/McH5l7urUG

In traditional descriptions of the disease, the myelin sheaths surrounding nerve-cell axons are the main target; peripheral nerve myelin, although structurally similar, is unaffected.

The disease typically manifests with discrete focal attacks that affect vision, sensation, strength, and balance, and over time the frequency of attacks decreases and progressive worsening with prominent neuronal injury supervenes (seen in figure). In a minority of patients, symptoms are progressive from onset. Diagnosis rests on clinical criteria and magnetic resonance imaging (MRI) findings, supplemented by clonal expansions of immunoglobulin in cerebrospinal fluid and slowing in central nerve conduction velocities as measured by evoked potentials.

Learn more in the Review Article “Advances in Multiple Sclerosis” by Stephen L. Hauser, MD: https://t.co/McH5l7urUG